Helix Liabilities And Stockholders Equity from 2010 to 2024

HBP Stock  CAD 1.00  0.05  5.26%   
Helix BioPharma Liabilities And Stockholders Equity yearly trend continues to be very stable with very little volatility. Liabilities And Stockholders Equity is likely to drop to about 1.4 M. Liabilities And Stockholders Equity is the total of all liabilities and equity in the company, which should equal Helix BioPharma's total assets according to the accounting equation. View All Fundamentals
 
Liabilities And Stockholders Equity  
First Reported
2011-07-31
Previous Quarter
1.1 M
Current Value
1.5 M
Quarterly Volatility
4.7 M
 
Yuan Drop
 
Covid
Check Helix BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Helix BioPharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.3 K, Interest Expense of 6.7 K or Selling General Administrative of 2.8 M, as well as many indicators such as Price To Sales Ratio of 20.62, Dividend Yield of 0.0 or Days Sales Outstanding of 74.71. Helix financial statements analysis is a perfect complement when working with Helix BioPharma Valuation or Volatility modules.
  
This module can also supplement various Helix BioPharma Technical models . Check out the analysis of Helix BioPharma Correlation against competitors.

Pair Trading with Helix BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Helix Stock

  0.83GOOG Alphabet CDRPairCorr
  0.79AMZN Amazon CDRPairCorr
  0.79NVDA NVIDIA CDRPairCorr
  0.79BOFA Bank of AmericaPairCorr
  0.78JPM JPMorgan ChasePairCorr
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Helix Stock

Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.